Skip to content
Screener

Exelixis EXEL Business Segments — Development

Similar metrics at other companies

Northern Oil and Gas logo
NOGDevelopment
$0—
APA Corporation logo
APAEgypt — Development
$132.5M-5.2%
APA Corporation logo
APANorth Sea — Development
$24M-48.4%
APA Corporation logo
APAOther International — Development
$72M+513%
APA Corporation logo
APAUnited States — Development
$389.5M-24.6%
Intuitive Machines, Inc. logo
LUNRReportable Segment — Business development
$1.2M+140%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept exel:DevelopmentExpenses.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less:
Cost of goods sold20,65719,47040,61038,642
Drug discovery18,25221,35737,72839,610
Development150,522134,159286,237287,376
Selling, general, and administrative127,413112,931250,283233,706
Other segment items(1)63,37866,718124,616124,134
Interest income(14,210)(16,789)(30,337)(35,865)
Provision for income taxes50,62845,567107,84891,641

Item 1. Financial Statements.

FAQ

What is Exelixis's business segments — development?
Exelixis (EXEL) reported business segments — development of $150.52M in Q2 2026.
How has Exelixis's business segments — development changed year-over-year?
Exelixis's business segments — development increased by 12.2% year-over-year, from $134.16M to $150.52M.
What is the long-term trend for Exelixis's business segments — development?
Over 3 years (2022 to 2025), Exelixis's business segments — development has grown at a 2.9% compound annual growth rate (CAGR), from $521.62M to $567.84M.
What does business segments — development mean?
Captures the costs associated with clinical trials, regulatory filings, and the advancement of drug candidates through the pipeline. This represents the capital-intensive phase of moving a molecule from discovery to commercial approval.

Ask your AI about Exelixis's business segments — development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude